Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 June 2025 | Story André Damons | Photo Department of Science, Technology, and Innovation
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), and Jansie Niehaus, NSTF Executive Director and Company Director, at the Second Ministerial Belt and Road Science and Technology conference (BRT) in China.

Prof Motlalepula Matsabisa, a specialist in indigenous knowledge systems from the Department of Pharmacology at the University of the Free State (UFS), is part of a delegation with Prof Blade Nzimande, minister of Science, Technology, and Innovation (DSTI), to the Second Ministerial Belt and Road Science and Technology conference (BRT) in China. 

The conference is being held in Chengdu from 11-12 June 2025 and will gather representatives from state-level agencies, scientific academies, and innovation enterprises from countries involved in the Belt and Road Initiative, including members of the Association of Southeast Asian Nations (ASEAN) and the Shanghai Cooperation Organisation. The theme of the conference is “Together for Innovation, Development for All – Jointly Building a Scientific and Technological Innovation Community for the Belt and Road”. 

Prof Matsabisa, Research Director of the African Medicines Innovations and Technologies Development at the UFS, is the only person from a South African university to be invited by Prof Nzimande as part of this ministerial trip. Other members of the delegation include members from the minister’s department, CEOs and board members of agencies that report to the DSTI – namely Technology Innovation Agency (TIA), the National Science and Technology Forum (NSTF), Council for Scientific and Industrial Research (CSIR), National Advisory Council on Innovation, Human Sciences Research Council of South Africa, South African Council for Natural Scientific Professions, National Science and Technology Forum (NSTF), National Advisory Council on Innovation (NACI), South African National Space Agency and the National Research Foundation (NRF). 

As a guest professor at the Beijing University of Chinese Medicine (BUCM) in Beijing, Prof Matsabisa accompanied the delegation on a visit to the university where he has a longstanding relationship. The UFS has the only active university collaboration within the China-South African Science and Technology bilateral agreement.

 

Supporting around aspects of traditional medicine 

According to a statement on the South African government website, Prof Nzimande expressed the department’s intention to strengthen collaboration with the Beijing University and the Aerospace Research Institute of the Chinese Academy of Sciences, in the areas of indigenous knowledge systems and space science, respectively. The minister visited both the BUCM and the Aerospace Information Research Institute of the Chinese Academy of Sciences this week. 

“It is an honour to be part of the minister’s delegation given that I am the only person from a university amongst the agencies. The UFS is indeed very honoured to have been the only one identified to be in this ministerial trip. I am honoured to make connections with the decision-makers such as the chairperson of the board of TIA and the CEO of NSTF and all the other CEOs. It’s indeed an honour to share our work with people from NACI and the minister’s office at DSTI. This really could not have been a better opportune moment for me,” says Prof Matsabisa. 

According to him, he is there to support Prof Nzimande around aspects of traditional medicine as well as with his meeting with the Chinese Minister of Science and Technology during the signing of a letter of intent on traditional medicines including in the BRT conference where the minister will give a talk that will cover traditional medicines. Prof Matsabisa says he is looking forward to strengthening the relationships between the UFS and BUCM and China as well as sharing with the minister the joint projects and joint students from both institutions, hoping for continued support and funding.

“This trip has opened new opportunities. TIA has invited me and the UFS to be part of their new project on neurodegenerative diseases with Cuba. It was wonderful to hear that both the CEO and the chairperson of the board had already been briefed about me to be part of the project.

“It is also great to be present at the signing of the letter of intent on traditional medicine as it is important to know where the policies are heading.”

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept